Regression of internal melanoma metastases following application of topical imiquimod to overlying skin

Journal of Drugs in Dermatology

Volumn 10, Issue 3, 2011, Pages 302-305

  Miller, Anne K ^a   Dusing, Reginald ^a   Meggison, Aaron ^a   Aires, Daniel ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INTERLEUKIN 2;

ADULT; ANAMNESIS; ARTICLE; BASAL CELL CARCINOMA; CANCER REGRESSION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGOGASTRODUODENOSCOPY; HUMAN; HUMAN TISSUE; ILIAC FOSSA METASTASIS; LIVER METASTASIS; MALE; MELANOMA; METASTASIS; MYOCARDITIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TUMOR VOLUME;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 80053012857     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Lacarrubba F, et al. Advances in the use of topical imiquimod to treat dermatologic disorders. The Clin Risk Manag. 2008;4:87-97. (Pubitemid 351460934)
2. Miller RL, et al. Imiquimod applied topically: A novel immune response modifier and a new class of drug. Int J Immunopharmacol. 1999;21(1):1-14. (Pubitemid 29097684)
3. Sauder DN. Imiquimod: Modes of action. British Journal of Dermatology. 2003;149(Suppl 66):5-8. (Pubitemid 38064505)
4. American Society of Health-System Pharmacists. Imiquimod Topical. AHFS Consumer Medication Information. 2009.
5. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993, J Clin Oncol. 1999;17:2105-2116. (Pubitemid 29318842)
6. Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648. (Pubitemid 32786276)
7. SkinCancerNet. Who is most at risk for melanoma. Available at: http://www.skincarephysicians.com/skincancernet/who-is-most.html. Accessed December 21, 2009.
8. Greene MH. The genetics of hereditary melanoma and nevi. 1998 Update. Cancer. 1999;86(11):2464-2477. (Pubitemid 30007529)
9. Kalialis LV, Drzewiecki KT, Mohammadi M, et al. Spontaneous regression of metastases from malignant melanoma: Case report. Melanoma Res. 2008;18(4):279-283.
10. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: Chemotherapy. Semin Oncol. 2009;29(5):427-445.
11. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270-283.
12. Heber G, Helbil D, Ponitzsch I, et al. Complete remission of cutaneous or subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges. 2009;7(6):534-536.
13. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo melanoma. Ann Plast Surg. 2008;61(4):419-424.
14. Aldara: Package insert. Bristol, NJ: Graceway Pharmaceuticals; 2009.